The CAR-T cell therapy market centers on an innovative form of immunotherapy that reprograms a patient’s own T cells to recognize and eradicate cancer cells, delivering highly personalized treatments. Originally approved for certain blood cancers like leukemia and lymphoma, CAR-T therapy demonstrates remarkable efficacy compared to conventional treatments, particularly in challenging, treatment-resistant cases. Market growth is driven by rising cancer prevalence, increasing R&D investment, and supportive regulatory pathways. However, high treatment costs, complex manufacturing, and limited accessibility remain major barriers. Although North America leads the current market, emerging regions—especially in Asia-Pacific—are rapidly expanding access through supportive infrastructure and growing local research efforts.
According to Fortune Business Insights, the global CAR-T cell therapy market was valued at USD 4.38 billion in 2023 and is projected to grow from USD 6.37 billion in 2024 to USD 16.35 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% during the forecast period. In 2023, North America dominated the market with a 68.72% share.
In December 2023, Max Healthcare introduced CAR-T cell therapy in the Delhi-NCR region in partnership with ImmunoACT for the treatment of lymphomas and leukemias. This marks a pivotal step in expanding access to advanced immunotherapy in South Asia.